The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Open accessAbstract
: 1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia. 3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission. 4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications. 5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [3]
In the citing paper
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophrenia60.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [60]
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Existing drugs are poorly tolerated and exhibit little differences in efficacy (Lieberman et al., 2005).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 2×
“Newcomer et al. (1999) extended the findings of Krystal et al. (1994) by showing that declarative memory, the form impaired in schizophrenia, was quite sensitive to low dose ketamine infusion.”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Based upon the emerging pharmacology of the NMDAR, Javitt and Zukin (1991) proposed that the psychotomimetic effects of PCP were due to blockade of the NMDA receptors.”
BackgroundTripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“The glutamatergic synapse consists of a tight functional relationship among the presynaptic terminal, the postsynaptic spine and the ensheathing astrocyte end-foot (Araque et al., 1999; Coyle et al., 2002).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundLesion of striatal neurons with kainic acid provides a model for Huntington's chorea
COYLE, J. T., & SCHWARCZ, R. (1976) · Nature · doi:10.1038/263244a0 · Cited by 1,248 · cited 1×
“We focused on glutamatergic signal transduction before there was any evidence that it could be relevant to neuropsychiatric disorders (Coyle and Schwarcz, 1976).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun. 319:1281–1286. · DOI
Cited by
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Dendritic spine pathology in neuropsychiatric disorders
Penzes, P., Cahill, M. E., Jones, K. A., VanLeeuwen, J.-E., & Woolfrey, K. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2741 · Cited by 1,523
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophreni”
BackgroundCorrell, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911
Ross, C. A., Margolis, R. L., Reading, S. A. J., Pletnikov, M., & Coyle, J. T. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.015 · Cited by 686
“Evidence for a role of glutamate in schizophrenia also originated from pharmacology (Coyle, 2006).”
Self-citationGlutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
“…interactions, and thus it may be difficult to determine which is primary, with different authorities on the subject suggesting that both glutamate and dopamine drive abnormalities in the other system (Coyle, 2006; Harrison and Weinberger, 2005; Olney and Farber, 1995; Stone et al., 2007).”
BackgroundDopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
The Hippocampal Formation in Schizophrenia
Tamminga, C. A., Stan, A. D., & Wagner, A. D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09081187 · Cited by 582
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585
Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., & Harte, M. K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.004 · Cited by 530
“…exploration of the mechanisms by which NMDA receptor antagonism provides a relevant model of schizophrenia in animals (Jentsch and Roth, 1999; Coyle, 2006; Large, 2007-focusing on novel therapies; Morris et al. 2005; Mouri et al. 2007); the use of isolation rearing as a neurodevelopmental…”
BackgroundCognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
“There is evidence of impaired glutamatergic function in schizophrenia (Coyle, 2006), including impaired plasticity processes (Lewis and Gonzalez-Burgos, 2008b), and the clinical and biological effects of non-competitive NMDA receptor antagonists (such as ketamine and phencyclidine) suggest a role…”
BackgroundReelin, lipoprotein receptors and synaptic plasticity
Herz, J., & Chen, Y. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn2009 · Cited by 524
“Second, reduced functionality of NMDA receptors, possibly on crucial GABA-containing interneurons, has been proposed to contribute to the disorder (for a review, see Ref”
BackgroundAnti-NMDA receptor encephalitis in Japan: Long-term outcome without tumor removal
Iizuka, T., Sakai, F., Ide, T., Monzen, T., Yoshii, S., Iigaya, M., Suzuki, K., Lynch, D. R., Suzuki, N., Hata, T., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000278388.90370.c3 · Cited by 517
Genetic insights into the neurodevelopmental origins of schizophrenia
Birnbaum, R., & Weinberger, D. R. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.125 · Cited by 494
High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology
Dunlop, J., Bowlby, M., Peri, R., Vasilyev, D., & Arias, R. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2552 · Cited by 498
Oxidative stress in schizophrenia: An integrated approach
Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.008 · Cited by 472
Näätänen, R., Kujala, T., Escera, C., Baldeweg, T., Kreegipuu, K., Carlson, S., & Ponton, C. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.09.020 · Cited by 425
“F el m R. Näätänen et al. / Clinical Neurophysiology 123 (2012) 424–458 425 4.”
BackgroundInfluentialSchizophrenia, “Just the Facts”: What we know in 2008
Tandon, R., Keshavan, M. S., & Nasrallah, H. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.022 · Cited by 409
“(2003), Coyle (2006), Stone et al.”
NMDA receptors in clinical neurology: excitatory times ahead
Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70165-0 · Cited by 415
“In contrast, it has been proposed that underactivity of NMDARs may be associated with neurodevelopmental conditions, specifically schizophrenia (14).”
BackgroundComputational models of schizophrenia and dopamine modulation in the prefrontal cortex
Rolls, E. T., Loh, M., Deco, G., & Winterer, G. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2462 · Cited by 387
“Any factor that reduces the currents through the NMDA ( N -methyl- D -aspartate) receptors (NMDARs) on the pyramidal cells, as seems to occur in patients with schizophreni”
BackgroundCalcium signalling remodelling and disease
Berridge, M. J. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110766 · Cited by 391
Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., Seifritz, E., Repovs, G., Krystal, J. H., Murray, J. D., et al. (2018) · eLife · doi:10.7554/elife.35082 · Cited by 390
“Such artefacts can induce spuriously high statistical association across the brain (Yang et al., 2014a; Coyle, 2006).”
BackgroundMethodThe role of serotonin receptors in the action of atypical antipsychotic drugs
Meltzer, H., & Massey, B. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.007 · Cited by 381
Anticevic, A., Haut, K., Murray, J. D., Repovs, G., Yang, G. J., Diehl, C., McEwen, S. C., Bearden, C. E., Addington, J., Goodyear, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0566 · Cited by 379
“We tested the following 3 questions: (1) “Is CHR associated with thalamocortical dysconnectivity?” (2) “Is thalamocortical dysconnectivity more severe in CHR-C compared with CHR-NC patients?” and (3) “Is thalamocortical dysconnectivity associated with severity of psychotic symptoms at baseline?” Methods”
Redox dysregulation, neurodevelopment, and schizophrenia
Do, K. Q., Cabungcal, J. H., Frank, A., Steullet, P., & Cuenod, M. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.05.001 · Cited by 384
Altered global brain signal in schizophrenia
Yang, G. J., Murray, J. D., Repovs, G., Cole, M. W., Savic, A., Glasser, M. F., Pittenger, C., Krystal, J. H., Wang, X.-J., Pearlson, G. D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405289111 · Cited by 377
“, physiological, movement, scanner-related) (9), which can induce artifactual high correlations across the brain.”
BackgroundAcute mechanisms underlying antibody effects in anti–N‐methyl‐D‐aspartate receptor encephalitis
Moscato, E. H., Peng, X., Jain, A., Parsons, T. D., Dalmau, J., & Balice‐Gordon, R. J. (2014) · Annals of Neurology · doi:10.1002/ana.24195 · Cited by 367
“Several lines of evidence in animal models and humans had led to the hypothesis that NMDAR hypofunction in inhibitory interneurons led to disinhibition in corticolimbic regions, underpinning core symptom domains in schizophrenia.(16,37) We examined whether patient antibodies may have had disparate effects on excitator…”
ResultGlutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
“It has been proposed that impairments in NMDA receptor activity may contribute to the pathophysiology of schizophrenia (Coyle, 2006; Javitt and Zukin, 1991).”
BackgroundNon-Genetic Factors in Schizophrenia
Stilo, S. A., & Murray, R. M. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1091-3 · Cited by 311
Schizophrenia, “just the facts”: What we know in 2008Part 3: Neurobiology
KESHAVAN, M., TANDON, R., BOUTROS, N., & NASRALLAH, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.020 · Cited by 347
“Several genes implicated in schizophrenia appear to affect the glutamatergic system (Arnold et al., 2005; Coyle, 2006).”
BackgroundVisual mismatch negativity: a predictive coding view
Stefanics, G., KremláÄek, J., & Czigler, I. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00666 · Cited by 340
Sensory Processing in Schizophrenia: Neither Simple nor Intact
Javitt, D. C. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp110 · Cited by 327
Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior
Basu, A. C., Tsai, G. E., Ma, C.-L., Ehmsen, J. T., Mustafa, A. K., Han, L., Jiang, Z. I., Benneyworth, M. A., Froimowitz, M. P., Lange, N., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.130 · Cited by 338
Self-citationConn, P. J., Lindsley, C. W., & Jones, C. K. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.006 · Cited by 330
“An alternative approach might be to reduce excitatory glutamatergic transmission at key synapses, such as thalamocortical synapses in the PFC, by activation of metabotropic glutamate receptor subtypes 2 and 3 (mGlu2R and mGluR3) presynaptically located in these synapses [6,10,12,13,17,18].”
BackgroundFoss-Feig, J. H., Adkinson, B. D., Ji, J. L., Yang, G., Srihari, V. H., McPartland, J. C., Krystal, J. H., Murray, J. D., & Anticevic, A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.005 · Cited by 310
“Corticostriatal functional connectivity alterations also support neural disinhibition in SCZ (110).”
Wang, X.-J., & Krystal, J. H. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.018 · Cited by 312
Johannessen Landmark, C. (2008) · CNS Drugs · doi:10.2165/00023210-200822010-00003 · Cited by 316
NMDA receptors in nervous system diseases
Zhou, Q., & Sheng, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.030 · Cited by 298
“Clinical trials with glycine or D-serine (which target the glycine co-agonist site in NMDARs) aiming to enhance the activity and function of the glutamate system have produced mixed results (Coyle, 2006; Lindsley et al., 2006).”
InfluentialGleichman, A. J., Spruce, L. A., Dalmau, J., Seeholzer, S. H., & Lynch, D. R. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0064-12.2012 · Cited by 290
“NMDA receptors (NMDARs) are critical in learning and memory, and hypofunction of the receptor has been implicated in schizophrenia (Coyle, 2006).”
BackgroundBussey, T. J., Holmes, A., Lyon, L., Mar, A. C., McAllister, K. A. L., Nithianantharajah, J., Oomen, C. A., & Saksida, L. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.011 · Cited by 299
“We have used a touchscreen extinction task to test mice with mutations in various molecules of the glutamatergic system, a neurotransmitter system which has been repeatedly implicated in schizophrenia (Coyle, 2006).”
InfluentialThe origin of NMDA receptor hypofunction in schizophrenia
Nakazawa, K., & Sapkota, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107426 · Cited by 275
“…to speculate that NMDAR hypofunction takes places in cortical and hippocampal GABAergic neurons in idiopathic schizophrenia (Cohen et al., 2015; Coyle, 2006; Inan et al., 2013; Ju and Cui, 2016; Lisman et al., 2008; Moreau and Kullmann, 2013; Nakazawa et al., 2017; Nakazawa et al., 2012; Olney…”
BackgroundSavonenko, A. V., Melnikova, T., Laird, F. M., Stewart, K.-A., Price, D. L., & Wong, P. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710373105 · Cited by 290
“Nevertheless, BACE1 knockout mice represent an excellent model to clarify further the relationship between alterations in NRG1/ ErbB4 signaling and changes in glutamatergic and GABAergic functions implicated in pathophysiology of schizophrenia (16).”
BackgroundInfluentialSchmidt, C. J., Chapin, D. S., Cianfrogna, J., Corman, M. L., Hajos, M., Harms, J. F., Hoffman, W. E., Lebel, L. A., McCarthy, S. A., Nelson, F. R., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.132910 · Cited by 284
Fontana, B. D., Mezzomo, N. J., Kalueff, A. V., & Rosemberg, D. B. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.004 · Cited by 272
“questions about alternative approaches to modeling schizophrenia (Coyle, 2006; Coyle and Tsai, 2004; Coyle et al., 2002).”
BackgroundMethodInfluentialAltered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia
Kehrer, C. (2008) · Frontiers in Molecular Neuroscience · doi:10.3389/neuro.02.006.2008 · Cited by 287
“In recent years, the attention has, however, shifted to the glutamate system, the major excitatory neurotransmitter in the CNS and towards a concept of functional imbalance between excitatory and inhibitory transmission at the network level in various brain regions in schizophrenia.”
BackgroundThe Catatonia Syndrome: Forgotten but Not Gone
Fink, M., & Taylor, M. A. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.141 · Cited by 280
Lisman, J. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.10.018 · Cited by 270
“4) NMDAR antagonist, when given to normal subjects, produces many of the symptoms of SZ, suggesting that the disease involves NMDAR hypofunction [5,6].”
BackgroundPaul, S. M., Doherty, J. J., Robichaud, A. J., Belfort, G. M., Chow, B. Y., Hammond, R. S., Crawford, D. C., Linsenbardt, A. J., Shu, H.-J., Izumi, Y., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2619-13.2013 · Cited by 264
“…(PCP) produce psychotic symptoms and cognitive deficits (Luby et al., 1959) mimicking schizophrenia in humans (for review, see Tamminga, 1998; Coyle, 2006), there has been considerable interest in discovering drugs that augment NMDAR function to treat the debilitating negative and cognitive…”
BackgroundInfluentialSpontaneous Gamma Activity in Schizophrenia
Hirano, Y., Oribe, N., Kanba, S., Onitsuka, T., Nestor, P. G., & Spencer, K. M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2642 · Cited by 261
Fernández, E., Collins, M. O., Uren, R. T., Kopanitsa, M. V., Komiyama, N. H., Croning, M. D. R., Zografos, L., Armstrong, J. D., Choudhary, J. S., & Grant, S. G. N. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.27 · Cited by 274
“This suggests that the overall network and its various clusters might play a role in schizophrenia, and not simply the glutamate receptors, as was generally considered in the ‘glutamate hypothesis’ of schizophrenia (Greene, 2001; Coyle, 2006; Lisman et al, 2008).”
Gandal, M. J., Edgar, J. C., Klook, K., & Siegel, S. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.007 · Cited by 269
“Considerable evidence implicates reduced NMDA-receptor mediated signaling as the core pathophysiologic deficit of schizophrenia (e.g., the “Glutamate Hypothesis”) (Coyle, 2006; Goff and Coyle, 2001).”
Acetylcholine–Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders
Lester, D. B., Rogers, T. D., & Blaha, C. D. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00142.x · Cited by 259
“However, this simplified perspective of unilateral involvement of central DA systems in such a complex psychopathological disorder, has given way to inclusion of dysfunction in potentially more critical neurotransmitters such as glutamate and its interactions with DA systems [218,219].”
BackgroundStress and neurodevelopmental processes in the emergence of psychosis
Holtzman, C. W., Trotman, H. D., Goulding, S. M., Ryan, A. T., MacDonald, A. N., Shapiro, D. I., Brasfield, J. L., & Walker, E. F. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.017 · Cited by 244
“Indeed, administration of PCP and ketamine to healthy individuals often leads to cognitive deficits and symptoms characteristic of psychosis (for review, see Coyle, 2006).”
BackgroundGreenwood, T. A., Lazzeroni, L. C., Murray, S. S., Cadenhead, K. S., Calkins, M. E., Dobie, D. J., Green, M. F., Gur, R. E., Gur, R. C., Hardiman, G., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10050723 · Cited by 257
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
Snyder, M. A., & Gao, W.-J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00031 · Cited by 236
“Accumulating studies have shown that aberrant NMDAR function, namely NMDAR hypofunction, in the limbic brain region, may underlie many aspects of molecular, cellular, and behavioral abnormalities associated with schizophrenia (Mohn et al., 1999; Olney et al., 1999; Tamminga, 1999; Dracheva et al., 2001; Krystal et al.…”
BackgroundInfluentialNaatanen, R., Kujala, T., Kreegipuu, K., Carlson, S., Escera, C., Baldeweg, T., & Ponton, C. (2011) · Brain · doi:10.1093/brain/awr064 · Cited by 244
“…of the N-methyl-Daspartate receptors, corrected MMN deficiency for tone-frequency change in patients with schizophrenia, and there was also evidence for the improvement of the clinical condition (Berk et al., 2008) [for further supportive evidence, see Coyle, 2006 and Schwieler et al. (2008)].”
BackgroundInfluentialImpaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq112 · Cited by 253
Perez, V. B., Woods, S. W., Roach, B. J., Ford, J. M., McGlashan, T. H., Srihari, V. H., & Mathalon, D. H. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.038 · Cited by 246
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
MELTZER, H., & HUANG, M. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00909-6 · Cited by 248
Mismatch Negativity (MMN) as an Index of Cognitive Dysfunction
Näätänen, R., S. Sussman, E., Salisbury, D., & L. Shafer, V. (2014) · Brain Topography · doi:10.1007/s10548-014-0374-6 · Cited by 217
“At least, studies of patients with Schizophrenia (e.g., Olney and Farber 1995; Coyle 2006), stroke (e.g., Dhawan et al. 2010), and normal aging (e.g., Magnusson et al. 2010) have linked impaired NMDA receptors to reduced amplitude MMN.”
BackgroundKeshavan, M. S., Nasrallah, H. A., & Tandon, R. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.011 · Cited by 226
“…constructs such as the NMDA receptor hypofunction model have considerable explanatory power, and can integrate the early and late developmental deviations, the role of dopamine, as well as the post-illness onset deteriorative processes that occur in schizophrenia (Keshavan, 1999; Coyle, 2006).”
Development of allosteric modulators of GPCRs for treatment of CNS disorders
Nickols, H. H., & Conn, P. J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.013 · Cited by 226
“naling could provide efficacy in reducing the symptoms associated with schizophrenia (Coyle, 2006; Lindsley et al., 2006).”
The contribution of failing adult hippocampal neurogenesis to psychiatric disorders
Kempermann, G., Krebs, J., & Fabel, K. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282fad375 · Cited by 227
Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X.-M., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 220
“Glutamate—Glutamatergic synapses are the key excitatory synapses within the brain, and mechanisms of both hyperglutamatergic and hypoglutamatergic functioning have been implicated in the pathophysiology of schizophrenia (for review, see Olney et al., 1999; Deutsch et al., 2001; Coyle, 2006).”
BackgroundDysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia
Berridge, M. J. (2013) · Prion · doi:10.4161/pri.21767 · Cited by 211
Balu, D. T., Li, Y., Puhl, M. D., Benneyworth, M. A., Basu, A. C., Takagi, S., Bolshakov, V. Y., & Coyle, J. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304308110 · Cited by 217
Self-citationFabp7 Maps to a Quantitative Trait Locus for a Schizophrenia Endophenotype
Watanabe, A., Toyota, T., Owada, Y., Hayashi, T., Iwayama, Y., Matsumata, M., Ishitsuka, Y., Nakaya, A., Maekawa, M., Ohnishi, T., et al. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050297 · Cited by 218
“Importantly, the FABP7 gene, which is modestly associated with schizophrenia in the current study, has the potential to link together the three compelling etiological hypotheses of schizophrenia, namely the NMDA, developmental, and glial (astrocyte) theories [57,58].”
BackgroundNeuropsychiatric Disease and Toxoplasma gondii Infection
Henriquez, S. A., Brett, R., Alexander, J., Pratt, J., & Roberts, C. W. (2009) · Neuroimmunomodulation · doi:10.1159/000180267 · Cited by 206
“Glutamate is also thought to have an important role in schizophrenia, due to the analysis of the effects of the psychotic drugs ketamine and phencyclidine [”
BackgroundVitamin D cell signalling in health and disease
Berridge, M. J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.008 · Cited by 214
The Schizophrenia Susceptibility Gene dysbindin Controls Synaptic Homeostasis
Dickman, D. K., & Davis, G. W. (2009) · Science · doi:10.1126/science.1179685 · Cited by 206
Cell Type-Specific Development of NMDA Receptors in the Interneurons of Rat Prefrontal Cortex
Wang, H.-X., & Gao, W.-J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.20 · Cited by 203
“The long-standing dopamine hypothesis has been challenged by a hypofunction hypothesis of both NMDARs and inhibition (Olney and Farber, 1995; Moghaddam and Jackson, 2003; Coyle, 2006; Lindsley et al, 2006).”
BackgroundMeta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194
“Since, like other amino acids, glycine does not cross the blood-brain barrier (BBB), a relatively large amount of peripheral glycine is required for there to be a significant elevation in the brain level of glycine.([18])”
BackgroundGlutamatergic targets for new alcohol medications
Holmes, A., Spanagel, R., & Krystal, J. H. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3226-2 · Cited by 197
“2009) and schizophrenia (Coyle 2006).”
Marx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.26 · Cited by 193
“…to pregnenolone sulfate in humans following acute administration (Morley et al, 1997; Roberts, 1995), may thus represent a logical strategy for the amelioration of hypothesized NMDA receptor hypofunction in schizophrenia (Coyle, 2006; Javitt, 2004, 2007; Millan, 2005; Rujescu et al, 2006).”
InfluentialSerine racemase is associated with schizophrenia susceptibility in humans and in a mouse model
Labrie, V., Fukumura, R., Rastogi, A., Fick, L. J., Wang, W., Boutros, P. C., Kennedy, J. L., Semeralul, M. O., Lee, F. H., Baker, G. B., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp261 · Cited by 185
“Schizophrenia is known to be influenced by heritable factors and genetic studies have identified a number of susceptibility genes that modulate NMDAR function (2,4).”
BackgroundMethodCerebral cortex : principles of operation
Rolls, E. T. (2016) · doi:10.82444/warw.33712699 · Cited by 175
Extracellular glutamate: functional compartments operate in different concentration ranges
Moussawi, K., Riegel, A., Nair, S., & Kalivas, P. W. (2011) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2011.00094 · Cited by 184
“Importantly, neuropsychiatric diseases have been linked to neuropathologies in mGluRs and glial glutamate release and uptake that in turn alter how mGluRs regulate the potentiation and depotentiation of excitatory transmission (Coyle, 2006; Luscher and Huber, 2009; Moussawi et al., 2009; Yang et al., 2009).”
BackgroundWiedholz, L. M., Owens, W. A., Horton, R. E., Feyder, M., Karlsson, R.-M., Hefner, K., Sprengel, R., Celikel, T., Daws, L. C., & Holmes, A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002056 · Cited by 180
Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia
Berridge, M. J. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1806-z · Cited by 181
“This defect in the ability of the NMDARs on the inhibitory interneurons to respond to glutamate is the basis of the NMDAR hypofunction hypothesis of schizophrenia (Coyle 2006; Kantrowitz and Javitt 2010; Nakazawa et al. 2012; Snyder and Gao 2013).”
BackgroundShamir, A., Kwon, O.-B., Karavanova, I., Vullhorst, D., Leiva-Salcedo, E., Janssen, M. J., & Buonanno, A. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1899-11.2012 · Cited by 175
“Maintaining the balance between excitation and inhibition is important for the homeostatic control of normal brain function and behavior, and imbalances are believed to contribute to the pathology of multiple psychiatric disorders, including schizophrenia (Benes and Berretta, 2001; Coyle, 2006; Kehrer et al., 2008; Li…”
BackgroundThe neuregulin signaling pathway and schizophrenia: From genes to synapses and neural circuits
Buonanno, A. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.07.012 · Cited by 173
The neurobiology of D-amino acid oxidase and its involvement in schizophrenia
Verrall, L., Burnet, P. W. J., Betts, J. F., & Harrison, P. J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.99 · Cited by 170
Nutritional and medicinal aspects of d-amino acids
Friedman, M., & Levin, C. E. (2012) · Amino Acids · doi:10.1007/s00726-011-0915-1 · Cited by 168
Mitochondrial aspartate aminotransferase: a third kynurenate‐producing enzyme in the mammalian brain
Guidetti, P., Amori, L., Sapko, M. T., Okuno, E., & Schwarcz, R. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04556.x · Cited by 166
Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression
Chung, W., Choi, S. Y., Lee, E., Park, H., Kang, J., Park, H., Choi, Y., Lee, D., Park, S.-G., Kim, R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3927 · Cited by 163
DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release
Chen, X.-W., Feng, Y.-Q., Hao, C.-J., Guo, X.-L., He, X., Zhou, Z.-Y., Guo, N., Huang, H.-P., Xiong, W., Zheng, H., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200711021 · Cited by 161
“Vol. 181 No. 5 791–801 www.jcb.org/cgi/doi/ JCB 791 10.1083/jcb.200711021 X.-W. Chen and Y.-Q. Feng contributed equally to this paper.”
BackgroundInfluentialKarlsson, R.-M., Tanaka, K., Saksida, L. M., Bussey, T. J., Heilig, M., & Holmes, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.215 · Cited by 165
“Glutamatergic dysfunction is implicated in the pathophysiology of various neuropsychiatric conditions, including schizophrenia (Coyle, 2006; Harrison and Weinberger, 2005; Krystal et al, 2002; Lewis and Gonzalez-Burgos, 2006; Olney et al, 1999).”
Basal ganglia pathology in schizophrenia: dopamine connections and anomalies
Pérez‐Costas, E., Meléndez‐Ferro, M., & Roberts, R. C. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06604.x · Cited by 172
Metabolome in schizophrenia and other psychotic disorders: a general population-based study
Orešič, M., Tang, J. P., Seppänen‐Laakso, T., Mattila, I. M., Saarni, S. E., Saarni, S. I., Lönnqvist, J. K., Sysi‐Aho, M., Hyötyläinen, T., Perälä, J., et al. (2011) · Genome Medicine · doi:10.1186/gm233 · Cited by 166
“Glutamate has been hypothesized to play an important role in schizophrenia [55].”
BackgroundGray Matter Deficits, Mismatch Negativity, and Outcomes in Schizophrenia
Rasser, P. E., Schall, U., Todd, J., Michie, P. T., Ward, P. B., Johnston, P., Helmbold, K., Case, V., Soyland, A., Tooney, P. A., et al. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp060 · Cited by 158
“There is clear evidence of structural brain abnormalities in established schizophrenia,(16,17) and glutamate hypofunction has also been implicated in the neuropathological processes that can lead to cortical gray matter decline.(7,8,18) Furthermore,MMNreduction, as a putative measure of NMDA dysfunction, has been repo…”
BackgroundGenetic associations with schizophrenia: Meta-analyses of 12 candidate genes
Shi, J., Gershon, E. S., & Liu, C. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.06.016 · Cited by 160
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript et al., 2003; Coyle, 2006; Lindsley et al., 2006; Moghaddam, 2003).”
BackgroundHasan, A., Nitsche, M. A., Rein, B., Schneider-Axmann, T., Guse, B., Gruber, O., Falkai, P., & Wobrock, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.017 · Cited by 156
Chatterjee, M., Verma, R., Ganguly, S., & Palit, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.041 · Cited by 162
“Role of hypofunctional glutamatergic transmission via interplay between NMDA receptor and GABA receptor systems in the pathophysiology of schizophrenia has been widely reported (Olney and Farber, 1995; Coyle, 2006; Stahl, 2007).”
Functional hierarchy underlies preferential connectivity disturbances in schizophrenia
Yang, G. J., Murray, J. D., Wang, X.-J., Glahn, D. C., Pearlson, G. D., Repovs, G., Krystal, J. H., & Anticevic, A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508436113 · Cited by 153
“In contrast, the devastating cognitive deficits in SCZ may relate to abnormal glutamatergic signaling (93, 94) upstream of the dopaminergic dysregulation (5).”
BackgroundGlutamate Dysfunction in Hippocampus: Relevance of Dentate Gyrus and CA3 Signaling
Tamminga, C. A., Southcott, S. A., Sacco, C., Wagner, A. D., & Ghose, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs062 · Cited by 162
Biological factors underlying sex differences in neurological disorders
Loke, H., Harley, V. R., & Lee, J. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.05.024 · Cited by 165
Kremláček, J., Kreegipuu, K., Tales, A., Astikainen, P., Põldver, N., Näätänen, R., & Stefanics, G. (2016) · Cortex · doi:10.1016/j.cortex.2016.03.017 · Cited by 159
“This is further corroborated by parallel evidence for a key role of NMDAR in MMN generation and in the pathophysiology of schizophrenia (Coyle, 2006; Umbricht & Krljes, 2005; Javitt, 2009).”
ResultUnconventional NMDA Receptor Signaling
Doré, K., Stein, I. S., Brock, J. A., Castillo, P. E., Zito, K., & Sjöström, P. J. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1825-17.2017 · Cited by 152
“Abnormalities in NMDAR signaling, specifically a dysregulation or hypofunction of NMDARs, have also been implicated in schizophrenia (Coyle, 2006).”
BackgroundAdolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models
O'Donnell, P. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr028 · Cited by 145
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia, and the transmitters involved include dopamine (DA), glutamate, and gamma amino butyric acid (GABA).(2,3) DA is critical for modulating both excitatory glutamate transmission and local inhibition mediated by GABA.”
Marek, G. J., Behl, B., Bespalov, A., Groß, G., Lee, Y., & Schoemaker, H. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.059865 · Cited by 164
“The latter outcome has been attributed to a putative intrinsic component of clozapine enhancing glutamatergic neurotransmission (Coyle, 2006).”
Background
Metadata
- Authors
- Coyle, J. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Coyle, Joseph T.
- ORCID
- Coyle, Joseph T.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2006-06-14
- Volume
- 26
- Issue
- 4-6
- Pages
- 363-382
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11881825
- OpenAlex
- W2008639041
- Cited by
- 917
- References
- 159
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 16 · 2023: 29 · 2022: 29 · 2021: 28 · 2020: 35 · 2019: 47 · 2018: 43 · 2017: 44 · 2016: 45 · 2015: 56 · 2014: 47 · 2013: 74 · 2012: 62
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (P50MH060450, MH P50-60450, MH R01-572901)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, glutamate, NMDA receptor, dopamine hypothesis, negative symptoms, cognitive impairment, NMDA receptor antagonists, schizophrenia risk genes, GABAergic interneurons, antipsychotic drugs, glutamatergic neurotransmission
- MeSH terms
- Animals, Dopamine, Glutamates, Humans, Models, Biological, Synaptic Transmission, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.